Celltrion phase I data for biosimilar to Genentech’s Actemra® (tocilizumab)

Celltrion has released its clinical phase I data for its tocilizumab product CT-P47, biosimilar to Roche’s Actemra® which it announced at the 2023 European Congress of Rheumatology (2023 EULAR).  Celltrion has successfully demonstrated pharmacodynamic equivalence and safety comparable to Actemra®.  

Last week Celltrion filed MAA with EMA for biosimilar to Janssen’s Stelara® (ustekinumab).